Ocular Hypertension - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 137 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Ocular Hypertension - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Ocular Hypertension - Pipeline Review, H2 2016', provides an overview of the Ocular Hypertension pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ocular Hypertension
- The report reviews pipeline therapeutics for Ocular Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Ocular Hypertension therapeutics and enlists all their major and minor projects
- The report assesses Ocular Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Ocular Hypertension

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table Of Content

Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Ocular Hypertension Overview 11
Therapeutics Development 12
Pipeline Products for Ocular Hypertension - Overview 12
Pipeline Products for Ocular Hypertension - Comparative Analysis 13
Ocular Hypertension - Therapeutics under Development by Companies 14
Ocular Hypertension - Therapeutics under Investigation by Universities/Institutes 16
Ocular Hypertension - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Ocular Hypertension - Products under Development by Companies 20
Ocular Hypertension - Products under Investigation by Universities/Institutes 22
Ocular Hypertension - Companies Involved in Therapeutics Development 23
Aerie Pharmaceuticals, Inc. 23
Allergan Plc 24
Amakem NV 25
Bausch & Lomb Incorporated 26
Can-Fite BioPharma Ltd. 27
D. Western Therapeutics Institute, Inc. 28
F. Hoffmann-La Roche Ltd. 29
Inotek Pharmaceuticals Corporation 30
Ironwood Pharmaceuticals, Inc. 31
Kowa Company, Ltd. 32
Laboratoires Thea S.A. 33
Laboratorios Sophia S.A. de C.V. 34
Lee's Pharmaceutical Holdings Limited 35
Lexicon Pharmaceuticals, Inc. 36
NicOx S.A. 37
Ocular Therapeutix, Inc. 38
Otsuka Holdings Co., Ltd. 39
pSivida Corp. 40
Sanofi 41
Santen Pharmaceutical Co., Ltd. 42
Senju Pharmaceutical Co., Ltd. 43
Sylentis S.A.U. 44
ViSci Ltd. 45
Ocular Hypertension - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Combination Products 47
Assessment by Target 48
Assessment by Mechanism of Action 50
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
(bimatoprost + brimonidine tartarate + timolol maleate) - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
(bimatoprost + timolol maleate) - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
(carteolol hydrochloride + latanoprost) - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
(latanoprost + netarsudil mesylate) - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
(latanoprost + timolol maleate) - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
(latanoprost + trabodenoson) - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
AMA-0076 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
bamosiran - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
bimatoprost - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
bimatoprost SR - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
DE-117 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Gene Therapy to Target Matrix Metalloproteinase 1 for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
H-1129 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
IWP-953 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
latanoprost - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
latanoprost - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
latanoprost SR - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
latanoprost SR - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
latanoprost SR - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
latanoprostene bunod - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
levobetaxolol hydrochloride - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
LX-7101 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
MGV-354 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
NCX-1653 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
NCX-470 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
NCX-667 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
netarsudil mesylate - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
OPA-6566 - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
piclidenoson - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
PRO-067 - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
RG-4929 - Drug Profile 107
Product Description 107
Mechanism Of Action 107
R&D Progress 107
ripasudil - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
RO-5093151 - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
SAR-366234 - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
Sepetaprost - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
SNJ-1656 - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
trabodenoson - Drug Profile 115
Product Description 115
Mechanism Of Action 115
R&D Progress 115
travoprost SR - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
travoprost XR - Drug Profile 120
Product Description 120
Mechanism Of Action 120
R&D Progress 120
Ocular Hypertension - Dormant Projects 122
Ocular Hypertension - Discontinued Products 124
Ocular Hypertension - Product Development Milestones 125
Featured News & Press Releases 125
Jun 16, 2016: Aerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of Rhopressa (netarsudil ophthalmic solution) 0.02% 125
May 05, 2016: Aerie Pharmaceuticals Completes Enrollment of Mercury 1 Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% 125
Apr 27, 2016: Ocular Therapeutix Completes End-of-Phase 2 Review with FDA for OTX-TP (Sustained Release Travoprost) for Glaucoma and Ocular Hypertension 126
Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting 126
Apr 11, 2016: Inotek Pharmaceuticals Announces the Journal of Ocular Pharmacology and Therapeutics has Published its Phase 2 Data for Trabodenoson in Patients with Glaucoma and Ocular Hypertension 127
Mar 28, 2016: Aerie Pharmaceuticals Initiates Second Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% 128
Mar 17, 2016: Aerie Pharmaceuticals Reports Update on Positive Safety Results for Rhopressa QD (netarsudil ophthalmic solution) 0.02% 128
Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting 129
Feb 22, 2016: Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week 130
Feb 17, 2016: Aerie Pharmaceuticals Reports Positive Rhopressa QD (netarsudil ophthalmic solution) 0.02% 12 Month Interim Safety Results for Rocket 2 131
Feb 16, 2016: Ocular Therapeutix Announces Phase 3 Clinical Development Plan for OTX-TP, an Innovative Therapy for Glaucoma and Ocular Hypertension 131
Oct 22, 2015: Ocular Therapeutix Reports on Topline Results of Phase 2b Glaucoma Clinical Trial 132
Oct 01, 2015: New Drug Application for Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension 134
Sep 24, 2015: Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial of Rhopressa 134
Sep 21, 2015: Aerie Pharmaceuticals Initiates First Phase 3 Registration Trial of Roclatan 135
Appendix 136
Methodology 136
Coverage 136
Secondary Research 136
Primary Research 136
Expert Panel Validation 136
Contact Us 136
Disclaimer 137

List Of Tables

Number of Products under Development for Ocular Hypertension, H2 2016 12
Number of Products under Development for Ocular Hypertension - Comparative Analysis, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Number of Products under Development by Companies, H2 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Comparative Analysis by Late Stage Development, H2 2016 17
Comparative Analysis by Clinical Stage Development, H2 2016 18
Comparative Analysis by Early Stage Development, H2 2016 19
Products under Development by Companies, H2 2016 20
Products under Development by Companies, H2 2016 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2016 22
Ocular Hypertension - Pipeline by Aerie Pharmaceuticals, Inc., H2 2016 23
Ocular Hypertension - Pipeline by Allergan Plc, H2 2016 24
Ocular Hypertension - Pipeline by Amakem NV, H2 2016 25
Ocular Hypertension - Pipeline by Bausch & Lomb Incorporated, H2 2016 26
Ocular Hypertension - Pipeline by Can-Fite BioPharma Ltd., H2 2016 27
Ocular Hypertension - Pipeline by D. Western Therapeutics Institute, Inc., H2 2016 28
Ocular Hypertension - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 29
Ocular Hypertension - Pipeline by Inotek Pharmaceuticals Corporation, H2 2016 30
Ocular Hypertension - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016 31
Ocular Hypertension - Pipeline by Kowa Company, Ltd., H2 2016 32
Ocular Hypertension - Pipeline by Laboratoires Thea S.A., H2 2016 33
Ocular Hypertension - Pipeline by Laboratorios Sophia S.A. de C.V., H2 2016 34
Ocular Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 35
Ocular Hypertension - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016 36
Ocular Hypertension - Pipeline by NicOx S.A., H2 2016 37
Ocular Hypertension - Pipeline by Ocular Therapeutix, Inc., H2 2016 38
Ocular Hypertension - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 39
Ocular Hypertension - Pipeline by pSivida Corp., H2 2016 40
Ocular Hypertension - Pipeline by Sanofi, H2 2016 41
Ocular Hypertension - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 42
Ocular Hypertension - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016 43
Ocular Hypertension - Pipeline by Sylentis S.A.U., H2 2016 44
Ocular Hypertension - Pipeline by ViSci Ltd., H2 2016 45
Assessment by Monotherapy Products, H2 2016 46
Assessment by Combination Products, H2 2016 47
Number of Products by Stage and Target, H2 2016 49
Number of Products by Stage and Mechanism of Action, H2 2016 51
Number of Products by Stage and Route of Administration, H2 2016 53
Number of Products by Stage and Molecule Type, H2 2016 55
Ocular Hypertension - Dormant Projects, H2 2016 122
Ocular Hypertension - Dormant Projects (Contd..1), H2 2016 123
Ocular Hypertension - Discontinued Products, H2 2016 124